Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny blood cells may hold key to septic shock damage

NCT ID NCT02635854

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how platelets (small blood cells that help with clotting) become activated in people with septic shock, a life-threatening infection that causes organ failure. Researchers measured specific markers on platelets and platelet-white blood cell clumps in 27 patients. The goal was to understand if these changes contribute to organ damage, which could lead to better treatments in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Mar 2016

Finished

Jan 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: EXPERIMENTAL GROUP * Patient who possibly gave an oral agreement to inclusion and may sign a consent once out of intensive care * Patients hospitalized in general intensive care * Patient hospitalized for less than 72 hours * Patient suffering from severe sepsis, whatever their origin, with hypotension (PAs \<90mmHg) despite adequate fluid resuscitation and vasoactive requiring the use of amines, with hypoperfusion and / or at least one organ dysfunction ( septic shock) * Patient with a Sequential Organ Failure Assessment (SOFA) score\> 8 (or\> 2 in an organ) in the first 24 hours * Patient enjoying a social security scheme or equivalent CONTROL GROUP * Signed informed consent * Patient seen anesthesia consultation for orthopedic knee prosthesis of laying or hip with a negative balance infectious * Patient enjoying a social security scheme or equivalent Exclusion Criteria: EXPERIMENTAL GROUP * Patient on safeguarding justice, guardianship * Patient suffering from a haematological malignancy (leukemia, lymphoma ...) * Patient suffering from thrombocytopenia or constitutional thrombopathy * Pregnant CONTROL GROUP * Patient on safeguarding justice, guardianship * Patient with infectious positive balance (dental, urinary tract) prior to surgery * Patient suffering from a haematological malignancy (leukemia, lymphoma ...) * Patient suffering from thrombocytopenia or constitutional thrombopathy * Pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

Contacts and locations

Locations

  • CHU Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.